CDIM"Fortnite Ran" ・ ・ ・ The corner of the platform model
On August 14, the popular game "Fortnite" was removed from the App Store and Google Play due to violations of the guidelines.
This is because the developer, Epic Games, launched its own payment method, "Epic Direct Payment." Apps such as mobile games are offered through Apple and Google stores, and in-game currency and items such as items are also paid for in this store. All these types of transactions have a fee called "Apple tax" or "platform tax", which is generally said to be 30%. Epic Games is 30% more than before! If you use "Epic Direct Payment", you can get the same service with up to 20% off. I don't think this can be overlooked from the perspective of platforms such as Apple and Google, but Epic Games, whose app was deleted, immediately sued Apple and others for antitrust violations, and apparently prepared quite carefully. It seems to be an action in.
Making a claim with a past Apple CM parody videoFortnite Official YouTube Video
Isn't platform tax rate 30% high?
Is this "platform tax" setting appropriate? If you cut out only here, you will think "30% is really high." However, since Apple and Google openly provided such development environment, payment system, advertisement through the store, privacy management etc. (that is, platform), the business operator could concentrate on the application development itself, and it was easy. It was also able to reach the user. Of course, the platform itself would have cost a lot of money, and it's hard to maintain. Even so, I think that it is Epic Games's view that this is a huge hit, and it is 30% all the time, and that's not true. I'm not very bright in this area, so I can't answer "How much is it?" I'm sorry... Can anyone please tell me if you are familiar with it?
Even medical AI is a platform!
Well, the introduction is longer, but it is medical image x AI. If you have a talented AI, it's not a good idea to use it. From the user's point of view, I think that it can be used in various ways on one platform and is a number.
The AI development that we see and hear now is being developed in units such as "detecting stroke" and "detecting gastric cancer." However, in actual clinical practice, it is rather rare to see that alone, and doctors are making more decisions. In other words, even if there is a stand-alone AI that specializes in something specific, when you actually use it, it seems that there are many cases where it will be a problem. That said, it's not very practical for a single company or team to develop a whole set of AI functions. Therefore, I think it will be important to be able to use multiple apps on the platform at the same time. It may be more attractive as a business to take a share on the platform rather than individual AI applications.
GE's AI-powered platform, Edison Platform, is exactly this concept. Siemens Healthcare incorporates AI-Rad Companion etc. in the cloud service teamplay, and Philips has started providing Health Suite Insights. We can see the desire of major global players to incorporate it into the medical system, integrate it, and bring it all. Japanese people such as Fujifilm's SYNAPSE SAI viewer and Canon ITS Medical's Medical Image Place are making a name for themselves, but electronic medical record players may not be very interested in this area ...
The field of diagnostic imaging is a field in which Japanese equipment manufacturers are in a global leading position. In clinical practice, Japan has a large amount of high-quality images, and I think that the doctors who read images have a high level of skill. So, I personally think that I would like Japanese players to do their best on the platform as well as the AI technology development as well as the image.
AI technology is rapidly being applied in the medical field, but how will it adapt to the world of medical information? From this point of view, it seems that it will be a hot topic in consulting in the healthcare field for a while.
Responsibility: Ai Ito
Ai Ito (CDI Medical Consultant Co., Ltd.)
Completed a master's course at the Graduate School of Pharmaceutical Sciences, Osaka University (pharmacist). Completed a master's degree at Kyoto University Graduate School of Medicine.
After working as a trading company, an independent venture capital firm, a healthcare / bio venture company, a management consulting firm, etc. Conducts consulting including strategy support and execution support, including mid-term business strategy, new business strategy, overseas development, open innovation strategy, etc., mainly in the life sciences and healthcare field.